ORPHA:667
Autosomal recessive malignant osteopetrosis
Also known as: Infantile malignant osteopetrosis
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
959
89.9th percentile
Trials
2
Interventional, condition-specific
Researchers
1,158
Distinct authors in sample
Gene link
TCIRG1
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare disorder of bone resorption characterized by generalized skeletal densification.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019026
- UMLS:C4272578
- NCIT:C129733
Additional Mondo synonyms (6)
OPTB · autosomal recessive malignant osteopetrosis · autosomal recessive osteopetrosis · autosomal recessive osteopetrosis (disease) · infantile malignant osteopetrosis · osteopetrosis (disease), autosomal recessive
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — TCIRG1
- LiteraturePresent
959 matched papers (482 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
2 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (TCIRG1).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
959
959 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
959 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
482 in the last 10 years · medium confidence · 89.9th percentile (publications denominator)
Phrase hits: 959 · MeSH hits: 0
Who's working on it?
1,158
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Villa A10 papers · 2025
CNR-IRGB, Milan Unit, via Fantoli 16/15, 20138 Milan, Italy.
Papers in Europe PMC - 02Sobacchi C9 papers · 2026
CNR-IRGB, Milan Unit, via Fantoli 16/15, 20138 Milan, Italy.
Papers in Europe PMC - 03Kornak U8 papers · 2025
Institut für Medizinische Genetik und Humangenetik, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Max Planck Institute for Molecular Genetics, Berlin, Germany; Berlin-Brandenburg Center for Regenerative Therapies, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. Electronic address: uwe.kornak@charite.de.
Papers in Europe PMC - 04Capo V6 papers · 2025
San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute.
Papers in Europe PMC - 05Imel EA6 papers · 2025
Departments of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA; Departments of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.
Papers in Europe PMC - 06Wang J6 papers · 2026
Department of Hematology and Oncology, Anhui Provincial Children's Hospital, Hefei 230022, China.
Papers in Europe PMC - 07Econs MJ5 papers · 2025
Departments of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Papers in Europe PMC - 08Elson A5 papers · 2025
Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot 76100, Israel. Electronic address: ari.elson@weizmann.ac.il.
Papers in Europe PMC - 09Geiger B5 papers · 2025
Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot 76100, Israel. Electronic address: Benny.geiger@weizmann.ac.il.
Papers in Europe PMC - 10Palagano E5 papers · 2024
CNR-IRGB, Milan Unit, via Fantoli 16/15, 20138 Milan, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
2
interventional trials for this specific condition
2 interventional trials matched this specific condition name; 1 currently recruiting in our sample. 15 trials are registered for osteopetrosis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
2 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 82.4th percentile).
medium confidence · 82.4th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
2 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07665021·RECRUITING·Gene-Modified Stem Cell Therapy for Children With Autosomal Recessive Osteopetrosis (ARO)
Conditions: Osteopetrosis·Matched via name phrase
Broader category: osteopetrosis
15
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26Likely covered — the policy lists Osteopetrosis as a category (Group 1), and this condition is a form of it. Confirm eligibility with a Centre of Excellence.
Group 1 — one-time curative treatment
Up to ₹50 lakh per patient
Financial support for treatment at notified Centres of Excellence (figures evolved from the original ₹20 lakh Group-1 ceiling).
Policy figures change. Verify current MoHFW / CoE guidance before relying on any amount. Verify
Centres of Excellence (15)
- All India Institute of Medical Sciences (AIIMS) — New Delhi, Delhi
- Maulana Azad Medical College — New Delhi, Delhi
- Sanjay Gandhi Post Graduate Institute of Medical Sciences — Lucknow, Uttar Pradesh
- Post Graduate Institute of Medical Education and Research (PGIMER) — Chandigarh, Chandigarh
- Centre for DNA Fingerprinting & Diagnostics with Nizam’s Institute of Medical Sciences — Hyderabad, Telangana
- King Edward Memorial Hospital — Mumbai, Maharashtra
- Institute of Post-Graduate Medical Education and Research (IPGMER) — Kolkata, West Bengal
- Centre for Human Genetics with Indira Gandhi Hospital — Bengaluru, Karnataka
- Institute of Child Health and Hospital for Children (ICH & HC) — Chennai, Tamil Nadu
- All India Institute of Medical Sciences (AIIMS) — Jodhpur, Rajasthan
- Sree Avittam Thirunal Hospital (SAT), Government Medical College — Thiruvananthapuram, Kerala
- All India Institute of Medical Sciences (AIIMS) — Bhopal, Madhya Pradesh
- Regional Institute of Medical Sciences (RIMS) — Imphal, Manipur
- All India Institute of Medical Sciences (AIIMS) — Patna, Bihar
- Assam Medical College & Hospital — Dibrugarh, Assam
Voluntary contributions / crowdfunding (separate from CoE funding): https://rarediseases.mohfw.gov.in/
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Autosomal recessive malignant osteopetrosis" OR "Infantile malignant osteopetrosis" OR "autosomal recessive osteopetrosis" OR "autosomal recessive osteopetrosis (disease)" OR "osteopetrosis (disease), autosomal recessive"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Autosomal recessive malignant osteopetrosis" OR "Infantile malignant osteopetrosis" OR "autosomal recessive osteopetrosis" OR "autosomal recessive osteopetrosis (disease)" OR "osteopetrosis (disease), autosomal recessive" OR "TCIRG1"
Recall-expansion terms: TCIRG1
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 2 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"osteopetrosis"
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: OPTB
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T14:49:41.382Z
